
According to the latest quarterly results, Alpa Laboratories achieved a significant turnaround in its March 2026 quarterly performance, reporting a consolidated net profit of ₹1.90 crore compared to a net loss of ₹2.12 crore in the corresponding quarter of the previous year. This represents a complete reversal from the company's financial position during the same period last year, with the latest quarter showing substantial improvement in profitability metrics.
The company demonstrated strong revenue growth in Q3 FY26, with revenue standing at ₹29.05 crore, reflecting a quarter-on-quarter increase of 10.62% from ₹26.26 crore and a year-on-year growth of 11.09%. This growth trajectory indicates improved business momentum and market demand for the company's products during the quarter.
The company's operational performance showed remarkable improvement with operating profit standing at ₹1.51 crore, reflecting a quarter-on-quarter increase of 167.41% from ₹-2.24 crore and a year-on-year growth of 104.05%. PBDT reached ₹2.39 crore, showing a quarter-on-quarter increase of 206.41% from ₹0.78 crore, while Profit Before Tax stood at ₹1.74 crore with a quarter-on-quarter increase of 1,481.82% from ₹0.11 crore. These operational improvements demonstrate enhanced cost management and operational efficiency strategies.
For the full financial year ended March 2026, Alpa Laboratories net profit declined 23.03% to ₹15.01 crore compared to ₹19.50 crore in the previous year ended March 2025. The company's sales also declined 5.90% to ₹105.81 crore during the full year period, down from ₹112.45 crore in the previous year. However, the latest quarterly results show signs of recovery with improved operational metrics and profitability indicators.